查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1701279

生物製药市场规模、份额、趋势分析报告：按分子、疾病、药物类型、药物开发类型、配方、地区、细分预测，2025-2030 年

Biopharmaceutical Market Size, Share & Trends Analysis Report By Molecule (Monoclonal Antibody, Insulin, Vaccine, Hormone), By Disease, By Drug Type, By Drug Development Type, By Formulation, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 225 Pages | 商品交期: 2-10个工作天内

价格

生物製药市场的成长和趋势

根据Grand View Research, Inc.的最新报告，到2030年全球生物製药市场规模预计将达到7,408.4亿美元，2025年至2030年期间的复合年增长率为8.87%。

主要成长动力包括慢性病盛行率上升、精准医疗对生技药品的采用增加以及生物製造技术的进步。强劲的研发投入、新型生技药品的监管核准以及生物相似药的日益普及进一步支持了这一增长。对单株抗体、细胞和基因疗法以及重组蛋白的日益增长的需求正在重塑肿瘤学、自体免疫疾病和罕见疾病的治疗方法。

生物製药产业管道依然强劲，积极探索针对多种适应症的基因疗法、基于 RNA 的疗法和双特异性抗体。 2024 年 11 月发表在《自然生物技术》上的 CRISPR 基因编辑疗法对镰状细胞疾病和β地中海贫血患者显示出持久益处。

2024年12月，Biogen和Samsung Bioepis联合研发的Adalimumab相似药获得EMA核准，扩大了自体免疫疾病治疗领域的市场竞争。这项策略性措施与全球生物相似药日益普及的趋势相吻合，解决了可负担性挑战并提高了优质生技药品的可及性。随着生物相似药在欧洲和亚洲变得越来越普遍，各公司正在利用具有成本效益的製造策略来扩大其在全球市场的份额。

此外，皮下生技药品的推出透过简化给药和减少对输液中心的依赖彻底改变了患者体验。艾伯维（AbbVie）的Infliximab单抗皮下製剂于 2025 年 2 月核准，预计将提高依从性和患者满意度，并占据显着的市场占有率。

作为行业进步的一部分，龙沙作为白金赞助商参加了 11 月 20 日至 22 日在新加坡举行的 2024 年生物製剂製造会议，重点关注大规模生技药品製造的创新。这项活动重点在于塑造下一代高效疗法的生技药品製剂製造趋势，包括一次性生物反应器、製程强化和人工智慧主导的生技药品开发。

这些策略倡议凸显了公司对生物製药创新、市场扩张和监管进步的关注，旨在改善全球患者的治疗效果。

生物製药市场报告重点

  • 根据分子类型，单株抗体将在 2024 年占整个市场的 61.05%，由于其高特异性、广泛的治疗应用以及在肿瘤学和自体免疫疾病方面不断增长的需求，占据市场主导地位。由于荷尔蒙在内分泌学和代谢疾病治疗中的应用日益广泛，预计预测期内荷尔蒙领域将以强劲的复合年增长率增长。
  • 根据疾病，由于癌症盛行率上升和生技药品核准增加，肿瘤学在市场上占据最大收入份额，到 2024 年将占整个市场的 31.00%。然而，预计免疫学领域在预测期内将以最快的速度成长。
  • 根据药品类型，专有（品牌）生物製药在 2024 年占据最大的销售份额，占整个市场的 77.86%。然而，由于监管部门核准的增加和成本节约倡议，生物相似药预计将在预测期内实现最快的复合年增长率。
  • 根据药物开发类型，生物製药开发外包将占据市场主导地位，到 2024 年将占整个市场的 56.15%。
  • 根据配方，注射生技药品（静脉注射、肌肉注射、皮下注射）在 2024 年占据最大的收入份额，占市场份额的 92.55%。然而，由于非侵入性药物传输技术的进步，吸入式和鼻腔生技药品预计将显着成长。
  • 根据给药途径，肠外给药（静脉注射、肌肉注射和肌肉注射）在 2024 年占据 88.74% 的市场份额，占据主导地位。预计吸入和鼻腔给药将在预测期内获得发展动力。
  • 根据製剂类型，由于严格的法律规范和生技药品治疗的复杂性，处方药将在 2024 年占据市场主导地位，占总收入的 96.90%。
  • 按分销管道划分，医院和专科诊所等非零售通路在 2024 年成为主要分销管道，占总销售额的 55.70%。
  • 生物製药产业的主要企业包括安进、辉瑞、诺华、赛诺菲、默克、罗氏控股、百健、Astra Zeneca、礼来和拜耳。
  • 2024年6月，再生元製药公司宣布，Kevzara（通用名： Sarilumab）已获得美国FDA核准，用于治疗2岁以上患者的活动性多关节型幼年特发性关节炎（pJIA）。此次核准为患有这种慢性发炎疾病的儿童提供了新的治疗选择。

目录

第一章调查方法与范围

第二章执行摘要

第三章生物製药市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 定价分析

第四章生物製药市场：分子类型业务分析

  • 2024 年和 2030 年分子类型市场占有率
  • 分子类型细分仪表板
  • 2018-2030 年按分子类型分類的市场规模、预测与趋势分析
  • 单株抗体
  • 干扰素
  • 胰岛素
  • 生长和凝血因子
  • 促红血球生成素
  • 疫苗
  • 荷尔蒙
  • 其他的

第五章生物製药市场：疾病业务分析

  • 2024年及2030年的疾病市场占有率
  • 疾病细分仪表板
  • 市场规模、预测与趋势分析（按疾病，2018-2030 年）
  • 肿瘤学
  • 血液系统疾病
  • 代谢紊乱
  • 感染疾病
  • 心血管疾病
  • 神经系统疾病
  • 免疫学
  • 其他的

第六章生物製药市场：按药物类型分類的业务分析

  • 2024 年和 2030 年各药物类型的市场占有率
  • 药品类型细分仪表板
  • 2018-2030 年药品市场规模、预测及趋势分析
  • 独特的品牌

第七章生物製药市场：药物开发类型业务分析

  • 2024 年和 2030 年药物开发类型市场占有率
  • 药物开发类型细分仪表板
  • 按药物开发类型分類的市场规模、预测和趋势分析（2018-2030 年）
  • 外包
  • 内部

第八章生物製药市场：製剂业务分析

  • 2024年及2030年的医药市场占有率
  • 配方细分仪表板
  • 2018 年至 2030 年市场规模、预测与趋势分析（按配方）
  • 注射剂（静脉注射、肌肉注射、皮下注射）
  • 吸入/鼻喷剂
  • 其他的

第九章生物製药市场：给药途径业务分析

  • 2024 年及 2030 年给药途径市场占有率
  • 给药途径细分仪表板
  • 按管理路线分類的市场规模、预测和趋势分析（2018-2030 年）
  • 肠外给药（静脉注射、肌肉注射、皮下注射）
  • 吸入/鼻腔
  • 其他的

第十章生物製药市场：製剂类型业务分析

  • 2024 年和 2030 年按製剂类型分類的市场占有率
  • 处方类型细分仪表板
  • 2018-2030 年按製剂类型分類的市场规模、预测与趋势分析
  • 处方药
  • 场外交易（OTC）

第 11 章生物製药市场：通路业务分析

  • 2024年及2030年分销通路市场占有率
  • 分销通路细分仪表板
  • 市场规模、预测与趋势分析（按分销管道，2018-2030 年）
  • 零售
  • 非零售

第 12 章生物製药市场：区域、估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
    • 2018-2030年各国情况
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第十三章竞争格局

  • 参与者概述
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • AbbVie Inc.
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • Sanofi
    • GSK plc.
    • AstraZeneca
    • Takeda Pharmaceutical Company Limited
    • Biogen
    • Eli Lilly and Company
    • Novo Nordisk A/S
    • Amgen Inc.
Product Code: GVR-4-68040-534-1

Biopharmaceutical Market Growth & Trends:

The global biopharmaceutical market size is anticipated to reach USD 740.84 billion by 2030, growing at a CAGR of 8.87% from 2025 to 2030, according to a new report by Grand View Research, Inc. Key growth drivers include the rising prevalence of chronic diseases, increasing adoption of biologics for precision medicine, and advancements in biomanufacturing technologies. The growth is further supported by strong research and development investments, regulatory approvals for novel biologics, and expanding biosimilar adoption. The growing demand for monoclonal antibodies, cell and gene therapies, and recombinant proteins is reshaping treatment approaches across oncology, autoimmune diseases, and rare disorders.

The biopharmaceutical industry pipeline remains robust, with active research in gene therapies, RNA-based therapeutics, and bispecific antibodies targeting multiple indications. A notable breakthrough includes CRISPR-based gene editing therapies published in Nature Biotechnology in November 2024, demonstrating durable responses in sickle cell disease and beta-thalassemia patients.

In December 2024, Biogen and Samsung Bioepis secured EMA approval for their biosimilar adalimumab, expanding market competition in autoimmune disease treatment. This strategic move aligns with increasing global biosimilar adoption, addressing affordability challenges and improving access to high-quality biologics. With biosimilar penetration increasing across Europe and Asia, companies are leveraging cost-effective production strategies to enhance global market presence.

Additionally, the launch of subcutaneous biologics is transforming patient treatment experiences, offering convenient administration and reducing dependency on infusion centers. AbbVie's subcutaneous formulation of infliximab, approved in February 2025, is expected to capture significant market share, improving adherence and patient satisfaction.

As part of industry advancements, Lonza participated as a Platinum Sponsor at the 2024 Biologics Manufacturing Conference held in Singapore from November 20-22, focusing on innovations in large-scale biologics production. The event highlighted biopharma manufacturing trends, including single-use bioreactors, process intensification, and AI-driven biologics development, shaping the next generation of high-efficacy therapies.

These strategic initiatives underscore the growing emphasis on biopharmaceutical innovation, market expansion, and regulatory advancements aimed at improving patient outcomes worldwide.

Biopharmaceutical Market Report Highlights:

  • Based on molecule type, monoclonal antibodies dominated the market in 2024, accounting for 61.05% of the total revenue due to their high specificity, broad therapeutic applications, and growing demand in oncology and autoimmune disorders. The hormone segment is projected to grow at a robust CAGR over the forecast period, driven by increasing adoption in endocrinology and metabolic disease treatments.
  • Based on disease, oncology led the market with the largest revenue share in 2024, accounting for 31.00% of the total market due to the rising prevalence of cancer and increasing approvals of biologic therapies. However, the immunology segment is expected to grow at the fastest rate over the forecast period.
  • Based on drug type, proprietary (branded) biopharmaceuticals held the largest revenue share in 2024, comprising 77.86% of the total market, attributed to continuous R&D investments and strong patent protection. However, biosimilars are expected to witness the fastest CAGR over the forecast period due to regulatory approvals and increasing cost-saving initiatives.
  • Based on drug development type, outsourced biopharmaceutical development dominated the market in 2024, accounting for 56.15% of the total revenue as companies increasingly leverage contract development and manufacturing organizations (CDMOs) to optimize costs and accelerate commercialization.
  • Based on formulation, injectable biologics (IV, IM, SC) held the largest revenue share in 2024, comprising 92.55% of the market, driven by their systemic absorption and effectiveness. However, inhalation and nasal biologics are expected to witness significant growth due to advancements in non-invasive drug delivery.
  • Based on route of administration, parenteral administration (IV, IM, SC) led the market in 2024, with an 88.74% share, as most biologics require systemic delivery. Inhalation and nasal routes are expected to gain traction over the forecast period.
  • Based on prescription type, prescription medicines dominated the market in 2024, accounting for 96.90% of the total revenue due to stringent regulatory oversight and the complexity of biologic therapies.
  • Based on sales channel, non-retail channels, including hospitals and specialty clinics, emerged as the dominant distribution channel in 2024, accounting for 55.70% of total revenue, reflecting the need for controlled administration and storage of biologics.
  • Key players operating in the biopharmaceutical industry include Amgen Inc.; Pfizer Inc.; Novartis AG; Sanofi; Merck & Co.; Roche Holding AG; Biogen Inc.; AstraZeneca; Eli Lilly and Company; and Bayer AG.
  • In June 2024, Regeneron Pharmaceuticals, Inc. announced the approval of Kevzara (sarilumab) by the U.S. FDA for the treatment of active Polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years and older. This approval provides a new treatment option for children affected by this chronic inflammatory condition.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Molecule Type
    • 1.2.2. Disease
    • 1.2.3. Drug Type
    • 1.2.4. Drug Development Type
    • 1.2.5. Formulation
    • 1.2.6. Route of Administration
    • 1.2.7. Prescription Type
    • 1.2.8. Sales Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Biopharmaceutical Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Pricing Analysis

Chapter 4. Biopharmaceutical Market: Molecule Type Business Analysis

  • 4.1. Molecule Type Market Share, 2024 & 2030
  • 4.2. Molecule Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Molecule Type , 2018 to 2030 (USD Million)
  • 4.4. Monoclonal Antibody
    • 4.4.1. Monoclonal Antibody Market, 2018 - 2030 (USD Million)
  • 4.5. Interferon
    • 4.5.1. Interferon Market, 2018 - 2030 (USD Million)
  • 4.6. Insulin
    • 4.6.1. Insulin Market, 2018 - 2030 (USD Million)
  • 4.7. Growth and Coagulation Factor
    • 4.7.1. Growth and Coagulation Factor Market, 2018 - 2030 (USD Million)
  • 4.8. Erythropoietin
    • 4.8.1. Erythropoietin Market, 2018 - 2030 (USD Million)
  • 4.9. Vaccine
    • 4.9.1. Vaccine Market, 2018 - 2030 (USD Million)
  • 4.10. Hormone
    • 4.10.1. Hormone Market, 2018 - 2030 (USD Million)
  • 4.11. Others
    • 4.11.1. Other Type Market, 2018 - 2030 (USD Million)

Chapter 5. Biopharmaceutical Market: Disease Business Analysis

  • 5.1. Disease Market Share, 2024 & 2030
  • 5.2. Disease Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Disease, 2018 to 2030 (USD Million)
  • 5.4. Oncology
    • 5.4.1. Oncology Market, 2018 - 2030 (USD Million)
  • 5.5. Blood Disorder
    • 5.5.1. Blood Disorder Market, 2018 - 2030 (USD Million)
  • 5.6. Metabolic Disease
    • 5.6.1. Metabolic Disease Market, 2018 - 2030 (USD Million)
  • 5.7. Infectious Disease
    • 5.7.1. Infectious Disease Market, 2018 - 2030 (USD Million)
  • 5.8. Cardiovascular Disease
    • 5.8.1. Cardiovascular Disease Market, 2018 - 2030 (USD Million)
  • 5.9. Neurological Disease
    • 5.9.1. Neurological Disease Market, 2018 - 2030 (USD Million)
  • 5.10. Immunology
    • 5.10.1. Immunology Market, 2018 - 2030 (USD Million)
  • 5.11. Others
    • 5.11.1. Other Type Market, 2018 - 2030 (USD Million)

Chapter 6. Biopharmaceutical Market: Drug Type Business Analysis

  • 6.1. Drug Type Market Share, 2024 & 2030
  • 6.2. Drug Type Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
  • 6.4. Proprietary (Branded)
    • 6.4.1. Proprietary (Branded) Market, 2018 - 2030 (USD Million)
    • 6.4.2. Biosimilars
      • 6.4.2.1. Biosimilars Market, 2018 - 2030 (USD Million)

Chapter 7. Biopharmaceutical Market: Drug Development Type Business Analysis

  • 7.1. Drug Development Type Market Share, 2024 & 2030
  • 7.2. Drug Development Type Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Drug Development Type, 2018 to 2030 (USD Million)
  • 7.4. Outsource
    • 7.4.1. Outsource Market, 2018 - 2030 (USD Million)
  • 7.5. In-house
    • 7.5.1. In-house Market, 2018 - 2030 (USD Million)

Chapter 8. Biopharmaceutical Market: Formulation Business Analysis

  • 8.1. Formulation Market Share, 2024 & 2030
  • 8.2. Formulation Segment Dashboard
  • 8.3. Market Size & Forecasts and Trend Analysis, by Formulation, 2018 to 2030 (USD Million)
  • 8.4. Injectables (IV, IM, SC)
    • 8.4.1. Injectables (IV, IM, SC) Market, 2018 - 2030 (USD Million)
  • 8.5. Inhalation/Nasal Sprays
    • 8.5.1. Inhalation/Nasal Sprays Market, 2018 - 2030 (USD Million)
  • 8.6. Other Formulations
    • 8.6.1. Other Formulations Market, 2018 - 2030 (USD Million)

Chapter 9. Biopharmaceutical Market: Route of Administration Business Analysis

  • 9.1. Route of Administration Market Share, 2024 & 2030
  • 9.2. Route of Administration Segment Dashboard
  • 9.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 9.4. Parenteral (IV, IM, SC)
    • 9.4.1. Parenteral (IV, IM, SC) Market, 2018 - 2030 (USD Million)
  • 9.5. Inhalation/Nasal
    • 9.5.1. Inhalation/Nasal Market, 2018 - 2030 (USD Million)
  • 9.6. Other Routes
    • 9.6.1. Other Routes Market, 2018 - 2030 (USD Million)

Chapter 10. Biopharmaceutical Market: Prescription Type Business Analysis

  • 10.1. Prescription Type Market Share, 2024 & 2030
  • 10.2. Prescription Type Segment Dashboard
  • 10.3. Market Size & Forecasts and Trend Analysis, by Prescription Type, 2018 to 2030 (USD Million)
  • 10.4. Prescription Medicines
    • 10.4.1. Prescription Medicines Market, 2018 - 2030 (USD Million)
  • 10.5. Over-the-counter (OTC) Medicines
    • 10.5.1. Over-the-counter (OTC) Medicines Market, 2018 - 2030 (USD Million)

Chapter 11. Biopharmaceutical Market: Sales Channel Business Analysis

  • 11.1. Sales Channel Market Share, 2024 & 2030
  • 11.2. Sales Channel Segment Dashboard
  • 11.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2018 to 2030 (USD Million)
  • 11.4. Retail Pharmacies
    • 11.4.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 11.5. Non-retail
    • 11.5.1. Non-retail Market, 2018 - 2030 (USD Million)

Chapter 12. Biopharmaceutical Market: Regional Estimates & Trend Analysis

  • 12.1. Regional Market Share Analysis, 2024 & 2030
  • 12.2. Regional Market Dashboard
  • 12.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 12.4. North America
    • 12.4.1. North America Biopharmaceutical Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 12.4.2. U.S.
      • 12.4.2.1. Key Country Dynamics
      • 12.4.2.2. Target Disease Prevalence
      • 12.4.2.3. Regulatory Framework
      • 12.4.2.4. Reimbursement Framework
      • 12.4.2.5. U.S. Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.4.3. Canada
      • 12.4.3.1. Key Country Dynamics
      • 12.4.3.2. Target Disease Prevalence
      • 12.4.3.3. Regulatory Framework
      • 12.4.3.4. Reimbursement Framework
      • 12.4.3.5. U.S. Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.4.4. Mexico
      • 12.4.4.1. Key Country Dynamics
      • 12.4.4.2. Target Disease Prevalence
      • 12.4.4.3. Regulatory Framework
      • 12.4.4.4. Reimbursement Framework
      • 12.4.4.5. Mexico Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.5. Europe
    • 12.5.1. Europe Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.5.2. UK
      • 12.5.2.1. Key Country Dynamics
      • 12.5.2.2. Target Disease Prevalence
      • 12.5.2.3. Regulatory Framework
      • 12.5.2.4. Reimbursement Framework
      • 12.5.2.5. Uk Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.5.3. Germany
      • 12.5.3.1. Key Country Dynamics
      • 12.5.3.2. Target Disease Prevalence
      • 12.5.3.3. Regulatory Framework
      • 12.5.3.4. Reimbursement Framework
      • 12.5.3.5. Germany Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.5.4. France
      • 12.5.4.1. Key Country Dynamics
      • 12.5.4.2. Target Disease Prevalence
      • 12.5.4.3. Regulatory Framework
      • 12.5.4.4. Reimbursement Framework
      • 12.5.4.5. France Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.5.5. Italy
      • 12.5.5.1. Key Country Dynamics
      • 12.5.5.2. Target Disease Prevalence
      • 12.5.5.3. Regulatory Framework
      • 12.5.5.4. Reimbursement Framework
      • 12.5.5.5. Italy Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.5.6. Spain
      • 12.5.6.1. Key Country Dynamics
      • 12.5.6.2. Target Disease Prevalence
      • 12.5.6.3. Regulatory Framework
      • 12.5.6.4. Reimbursement Framework
      • 12.5.6.5. Spain Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.5.7. Denmark
      • 12.5.7.1. Key Country Dynamics
      • 12.5.7.2. Target Disease Prevalence
      • 12.5.7.3. Regulatory Framework
      • 12.5.7.4. Reimbursement Framework
      • 12.5.7.5. Denmark Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.5.8. Sweden
      • 12.5.8.1. Key Country Dynamics
      • 12.5.8.2. Target Disease Prevalence
      • 12.5.8.3. Regulatory Framework
      • 12.5.8.4. Reimbursement Framework
      • 12.5.8.5. Sweden Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.5.9. Norway
      • 12.5.9.1. Key Country Dynamics
      • 12.5.9.2. Target Disease Prevalence
      • 12.5.9.3. Regulatory Framework
      • 12.5.9.4. Reimbursement Framework
      • 12.5.9.5. Norway Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.6. Asia Pacific
    • 12.6.1. Asia Pacific Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.6.2. Japan
      • 12.6.2.1. Key Country Dynamics
      • 12.6.2.2. Target Disease Prevalence
      • 12.6.2.3. Regulatory Framework
      • 12.6.2.4. Reimbursement Framework
      • 12.6.2.5. Japan Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.6.3. China
      • 12.6.3.1. Key Country Dynamics
      • 12.6.3.2. Target Disease Prevalence
      • 12.6.3.3. Regulatory Framework
      • 12.6.3.4. Reimbursement Framework
      • 12.6.3.5. China Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.6.4. India
      • 12.6.4.1. Key Country Dynamics
      • 12.6.4.2. Target Disease Prevalence
      • 12.6.4.3. Regulatory Framework
      • 12.6.4.4. Reimbursement Framework
      • 12.6.4.5. India Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.6.5. Australia
      • 12.6.5.1. Key Country Dynamics
      • 12.6.5.2. Target Disease Prevalence
      • 12.6.5.3. Regulatory Framework
      • 12.6.5.4. Reimbursement Framework
      • 12.6.5.5. Australia Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.6.6. South Korea
      • 12.6.6.1. Key Country Dynamics
      • 12.6.6.2. Target Disease Prevalence
      • 12.6.6.3. Regulatory Framework
      • 12.6.6.4. Reimbursement Framework
      • 12.6.6.5. South Korea Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.6.7. Thailand
      • 12.6.7.1. Key Country Dynamics
      • 12.6.7.2. Target Disease Prevalence
      • 12.6.7.3. Regulatory Framework
      • 12.6.7.4. Reimbursement Framework
      • 12.6.7.5. Thailand Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.7. Latin America
    • 12.7.1. Latin America Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.7.2. Brazil
      • 12.7.2.1. Key Country Dynamics
      • 12.7.2.2. Target Disease Prevalence
      • 12.7.2.3. Regulatory Framework
      • 12.7.2.4. Reimbursement Framework
      • 12.7.2.5. Japan Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.7.3. Argentina
      • 12.7.3.1. Key Country Dynamics
      • 12.7.3.2. Target Disease Prevalence
      • 12.7.3.3. Regulatory Framework
      • 12.7.3.4. Reimbursement Framework
      • 12.7.3.5. China Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 12.8. Middle East and Africa
    • 12.8.1. Middle East and Africa Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.8.2. South Africa
      • 12.8.2.1. Key Country Dynamics
      • 12.8.2.2. Target Disease Prevalence
      • 12.8.2.3. Regulatory Framework
      • 12.8.2.4. Reimbursement Framework
      • 12.8.2.5. South Africa Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.8.3. Saudi Arabia
      • 12.8.3.1. Key Country Dynamics
      • 12.8.3.2. Target Disease Prevalence
      • 12.8.3.3. Regulatory Framework
      • 12.8.3.4. Reimbursement Framework
      • 12.8.3.5. Saudi Arabia Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.8.4. UAE
      • 12.8.4.1. Key Country Dynamics
      • 12.8.4.2. Target Disease Prevalence
      • 12.8.4.3. Regulatory Framework
      • 12.8.4.4. Reimbursement Framework
      • 12.8.4.5. UAE Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 12.8.5. Kuwait
      • 12.8.5.1. Key Country Dynamics
      • 12.8.5.2. Target Disease Prevalence
      • 12.8.5.3. Regulatory Framework
      • 12.8.5.4. Reimbursement Framework
      • 12.8.5.5. Kuwait Biopharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 13. Competitive Landscape

  • 13.1. Participant Overview
  • 13.2. Company Market Position Analysis
  • 13.3. Company Categorization
  • 13.4. Strategy Mapping
  • 13.5. Company Profiles/Listing
    • 13.5.1. F. Hoffmann-La Roche Ltd
      • 13.5.1.1. Overview
      • 13.5.1.2. Financial Performance
      • 13.5.1.3. Product Benchmarking
      • 13.5.1.4. Strategic Initiatives
    • 13.5.2. Novartis AG
      • 13.5.2.1. Overview
      • 13.5.2.2. Financial Performance
      • 13.5.2.3. Product Benchmarking
      • 13.5.2.4. Strategic Initiatives
    • 13.5.3. AbbVie Inc.
      • 13.5.3.1. Overview
      • 13.5.3.2. Financial Performance
      • 13.5.3.3. Product Benchmarking
      • 13.5.3.4. Strategic Initiatives
    • 13.5.4. Johnson & Johnson Services, Inc.
      • 13.5.4.1. Overview
      • 13.5.4.2. Financial Performance
      • 13.5.4.3. Product Benchmarking
      • 13.5.4.4. Strategic Initiatives
    • 13.5.5. Merck & Co., Inc.
      • 13.5.5.1. Overview
      • 13.5.5.2. Financial Performance
      • 13.5.5.3. Product Benchmarking
      • 13.5.5.4. Strategic Initiatives
    • 13.5.6. Pfizer Inc.
      • 13.5.6.1. Overview
      • 13.5.6.2. Financial Performance
      • 13.5.6.3. Product Benchmarking
      • 13.5.6.4. Strategic Initiatives
    • 13.5.7. Bristol-Myers Squibb Company
      • 13.5.7.1. Overview
      • 13.5.7.2. Financial Performance
      • 13.5.7.3. Product Benchmarking
      • 13.5.7.4. Strategic Initiatives
    • 13.5.8. Sanofi
      • 13.5.8.1. Overview
      • 13.5.8.2. Financial Performance
      • 13.5.8.3. Product Benchmarking
      • 13.5.8.4. Strategic Initiatives
    • 13.5.9. GSK plc.
      • 13.5.9.1. Overview
      • 13.5.9.2. Financial Performance
      • 13.5.9.3. Product Benchmarking
      • 13.5.9.4. Strategic Initiatives
    • 13.5.10. AstraZeneca
      • 13.5.10.1. Overview
      • 13.5.10.2. Financial Performance
      • 13.5.10.3. Product Benchmarking
      • 13.5.10.4. Strategic Initiatives
    • 13.5.11. Takeda Pharmaceutical Company Limited
      • 13.5.11.1. Overview
      • 13.5.11.2. Financial Performance
      • 13.5.11.3. Product Benchmarking
      • 13.5.11.4. Strategic Initiatives
    • 13.5.12. Biogen
      • 13.5.12.1. Overview
      • 13.5.12.2. Financial Performance
      • 13.5.12.3. Product Benchmarking
      • 13.5.12.4. Strategic Initiatives
    • 13.5.13. Eli Lilly and Company
      • 13.5.13.1. Overview
      • 13.5.13.2. Financial Performance
      • 13.5.13.3. Product Benchmarking
      • 13.5.13.4. Strategic Initiatives
    • 13.5.14. Novo Nordisk A/S
      • 13.5.14.1. Overview
      • 13.5.14.2. Financial Performance
      • 13.5.14.3. Product Benchmarking
      • 13.5.14.4. Strategic Initiatives
    • 13.5.15. Amgen Inc.
      • 13.5.15.1. Overview
      • 13.5.15.2. Financial Performance
      • 13.5.15.3. Product Benchmarking
      • 13.5.15.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Biopharmaceutical Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 5 Global Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 6 Global Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 7 Global Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 8 Global Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 9 Global Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 Global Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 11 Global Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 12 North America Biopharmaceutical Market, by Country, 2018 - 2030 (USD Million)
  • Table 13 North America Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 14 North America Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 15 North America Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 16 North America Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 17 North America Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 18 North America Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 19 North America Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 20 North America Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 21 US Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 22 US Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 23 US Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 24 US Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 25 US Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 26 US Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 27 US Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 28 US Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 29 Canada Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 30 Canada Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 31 Canada Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 32 Canada Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 33 Canada Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 34 Canada Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 35 Canada Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 36 Canada Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 37 Mexico Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 38 Mexico Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 39 Mexico Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 40 Mexico Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 41 Mexico Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 42 Mexico Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 Mexico Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 44 Mexico Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 45 Europe Biopharmaceutical Market, by Country, 2018 - 2030 (USD Million)
  • Table 46 Europe Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 47 Europe Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 48 Europe Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 49 Europe Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 50 Europe Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 51 Europe Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 52 Europe Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 53 Europe Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 54 UK Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 55 UK Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 56 UK Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 57 UK Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 58 UK Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 59 UK Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 60 UK Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 61 UK Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 62 Germany Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 63 Germany Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 64 Germany Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 65 Germany Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 66 Germany Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 67 Germany Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 68 Germany Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 69 Germany Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 70 France Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 71 France Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 72 France Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 73 France Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 74 France Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 75 France Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 76 France Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 77 France Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 78 Italy Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 79 Italy Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 80 Italy Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 81 Italy Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 82 Italy Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 83 Italy Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 84 Italy Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 85 Italy Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 86 Spain Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 87 Spain Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 88 Spain Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 89 Spain Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 90 Spain Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 91 Spain Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 92 Spain Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 93 Spain Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 94 Norway Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 95 Norway Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 96 Norway Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 97 Norway Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 98 Norway Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 99 Norway Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 100 Norway Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 101 Norway Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 102 Denmark Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 103 Denmark Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 104 Denmark Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 105 Denmark Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 106 Denmark Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 107 Denmark Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 108 Denmark Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 109 Denmark Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 110 Sweden Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 111 Sweden Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 112 Sweden Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 113 Sweden Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 114 Sweden Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 115 Sweden Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 116 Sweden Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 117 Sweden Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 118 Asia Pacific Biopharmaceutical Market, by Country, 2018 - 2030 (USD Million)
  • Table 119 Asia Pacific Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 120 Asia Pacific Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 121 Asia Pacific Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 122 Asia Pacific Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 123 Asia Pacific Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 124 Asia Pacific Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 125 Asia Pacific Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 126 Asia Pacific Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 127 Japan Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 128 Japan Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 129 Japan Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 130 Japan Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 131 Japan Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 132 Japan Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 133 Japan Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 134 Japan Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 135 China Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 136 China Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 137 China Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 138 China Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 139 China Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 140 China Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 141 China Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 142 China Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 143 India Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 144 India Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 145 India Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 146 India Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 147 India Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 148 India Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 149 India Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 150 India Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 151 Australia Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 152 Australia Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 153 Australia Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 154 Australia Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 155 Australia Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 156 Australia Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 157 Australia Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 158 Australia Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 159 South Korea Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 160 South Korea Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 161 South Korea Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 162 South Korea Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 163 South Korea Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 164 South Korea Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 165 South Korea Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 166 South Korea Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 167 Thailand Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 168 Thailand Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 169 Thailand Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 170 Thailand Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 171 Thailand Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 172 Thailand Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 173 Thailand Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 174 Thailand Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 175 Latin America Biopharmaceutical Market, by Country, 2018 - 2030 (USD Million)
  • Table 176 Latin America Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 177 Latin America Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 178 Latin America Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 179 Latin America Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 180 Latin America Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 181 Latin America Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 182 Latin America Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 183 Latin America Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 184 Brazil Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 185 Brazil Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 186 Brazil Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 187 Brazil Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 188 Brazil Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 189 Brazil Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 190 Brazil Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 191 Brazil Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 192 Argentina Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 193 Argentina Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 194 Argentina Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 195 Argentina Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 196 Argentina Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 197 Argentina Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 198 Argentina Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 199 Argentina Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 200 Middle East & Africa Biopharmaceutical Market, by Country, 2018 - 2030 (USD Million)
  • Table 201 Middle East & Africa Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 202 Middle East & Africa Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 203 Middle East & Africa Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 204 Middle East & Africa Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 205 Middle East & Africa Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 206 Middle East & Africa Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 207 Middle East & Africa Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 208 Middle East & Africa Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 209 South Africa Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 210 South Africa Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 211 South Africa Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 212 South Africa Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 213 South Africa Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 214 South Africa Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 215 South Africa Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 216 South Africa Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 217 Saudi Arabia Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 218 Saudi Arabia Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 219 Saudi Arabia Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 220 Saudi Arabia Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 221 Saudi Arabia Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 222 Saudi Arabia Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 223 Saudi Arabia Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 224 Saudi Arabia Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 225 UAE Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 226 UAE Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 227 UAE Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 228 UAE Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 229 UAE Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 230 UAE Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 231 UAE Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 232 UAE Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)
  • Table 233 Kuwait Biopharmaceutical Market, by Molecule Type, 2018 - 2030 (USD Million)
  • Table 234 Kuwait Biopharmaceutical Market, by Disease, 2018 - 2030 (USD Million)
  • Table 235 Kuwait Biopharmaceutical Market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 236 Kuwait Biopharmaceutical Market, by Drug Development Type, 2018 - 2030 (USD Million)
  • Table 237 Kuwait Biopharmaceutical Market, by Formulation, 2018 - 2030 (USD Million)
  • Table 238 Kuwait Biopharmaceutical Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 239 Kuwait Biopharmaceutical Market, by Prescription Type, 2018 - 2030 (USD Million)
  • Table 240 Kuwait Biopharmaceutical Market, by Sales Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Biopharmaceutical market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Segment snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Parent market value, 2024 (USD billion)
  • Fig. 16 Market dynamics
  • Fig. 17 Global large pharma R&D spending in 2018 - 2023 (USD Billion)
  • Fig. 18 Porter's five forces analysis
  • Fig. 19 PESTLE analysis
  • Fig. 20 Biopharmaceutical market: Molecule type outlook and key takeaways
  • Fig. 21 Biopharmaceutical market: Molecule type movement analysis
  • Fig. 22 Monoclonal antibody market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 23 Interferon market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 24 Insulin market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 25 Growth and coagulation factor market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 26 Erythropoietin market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 27 Vaccines market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 28 Hormone market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 29 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 30 Biopharmaceutical market: Disease outlook and key takeaways
  • Fig. 31 Biopharmaceutical market: Disease movement analysis
  • Fig. 32 Oncology market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 33 Blood disorder market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 34 Metabolic disease market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 35 Infectious disease market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 36 Cardiovascular disease market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 37 Neurological disease market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 38 Immunology market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 39 Others market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 40 Biopharmaceutical market: Drug Type outlook and key takeaways
  • Fig. 41 Biopharmaceutical market: Drug type movement analysis
  • Fig. 42 Proprietary (Branded) market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 43 Biosimilars market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 44 Biopharmaceutical market: Drug development type outlook and key takeaways
  • Fig. 45 Biopharmaceutical market: Drug development type movement analysis
  • Fig. 46 Outsource market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 47 In-house market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 48 Biopharmaceutical market: Formulation outlook and key takeaways
  • Fig. 49 Biopharmaceutical market: Formulation movement analysis
  • Fig. 50 Injectable market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 51 Inhalation/nasal sprays market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 52 Other formulations market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 53 Biopharmaceutical market: Prescription outlook and key takeaways
  • Fig. 54 Biopharmaceutical market: Prescription movement analysis
  • Fig. 55 Prescription medicines market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 56 OTC market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 57 Biopharmaceuticals market: Route of administration outlook and key takeaways
  • Fig. 58 Biopharmaceuticals market: Route of administration movement analysis
  • Fig. 59 Parenteral market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 60 Inhalations/Nasal market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 61 Other routes of administration market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 62 Biopharmaceuticals market Sales channel market outlook and key takeaways
  • Fig. 63 Biopharmaceuticals market Sales channel market movement analysis
  • Fig. 64 Retail market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 65 Non-retail market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 66 Biopharmaceutical market revenue, by region, 2024 & 2030 (USD Billion)
  • Fig. 67 Regional marketplace: Key takeaways
  • Fig. 68 North America biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 69 Key country dynamics
  • Fig. 70 U.S. biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 71 Cancer incidence, 2022-2045
  • Fig. 72 U.S. healthcare system: money flow
  • Fig. 73 Key country dynamics
  • Fig. 74 Canada biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 75 Cancer incidence, 2022-2045
  • Fig. 76 Key country dynamics
  • Fig. 77 Mexico biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 78 Cancer incidence, 2022-2045
  • Fig. 79 Regulatory framework
  • Fig. 80 Europe biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 81 Obesity and diabetes in European nations
  • Fig. 82 Causes of mortality in Europe
  • Fig. 83 Key country dynamics
  • Fig. 84 UK biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 85 Cancer incidence, 2022-2045
  • Fig. 86 Key country dynamics
  • Fig. 87 Germany biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 88 Cancer incidence, 2022-2045
  • Fig. 89 R&D spending
  • Fig. 90 Exclusivity formula
  • Fig. 91 Germany insurance coverage
  • Fig. 92 Key country dynamics
  • Fig. 93 France biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 94 Cancer incidence, 2022-2045
  • Fig. 95 Key country dynamics
  • Fig. 96 Italy biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 97 Cancer incidence, 2022-2045
  • Fig. 98 Key country dynamics
  • Fig. 99 Spain biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 100 Cancer incidence, 2022-2045
  • Fig. 101 Key country dynamics
  • Fig. 102 Denmark biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 103 Cancer Incidence, 2022-2045
  • Fig. 104 Key country dynamics
  • Fig. 105 Sweden biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 106 Cancer incidence 2022-2045
  • Fig. 107 Key country dynamics
  • Fig. 108 Norway biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 109 Cancer incidence, 2022-2045
  • Fig. 110 Rest of Europe biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 111 Asia Pacific biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 112 Key country dynamics
  • Fig. 113 Japan biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 114 Cancer incidence, 2022-2045
  • Fig. 115 Japan pharmaceutical registration
  • Fig. 116 Key country dynamics
  • Fig. 117 China biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 118 Cancer incidence, 2022-2045
  • Fig. 119 Regulatory details: China
  • Fig. 120 Key country dynamics
  • Fig. 121 India biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 122 Cancer incidence, 2018 - 2030
  • Fig. 123 Key country dynamics
  • Fig. 124 Australia biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 125 Cancer incidence, 2018 - 2030
  • Fig. 126 Key country dynamics
  • Fig. 127 Thailand biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 128 Cancer incidence, 2018 - 2030
  • Fig. 129 Key country dynamics
  • Fig. 130 South Korea biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 131 Cancer incidence, 2018 - 2030
  • Fig. 132 Rest of Asia Pacific biopharmaceutical market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 133 Latin America biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 134 Key country dynamics
  • Fig. 135 Brazil biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 136 Cancer incidence, 2018 - 2030
  • Fig. 137 Key country dynamics
  • Fig. 138 Argentina biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 139 Cancer incidence, 2018 - 2030
  • Fig. 140 Rest of Latin America biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 141 MEA biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 142 Key country dynamics
  • Fig. 143 South Africa biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 144 Cancer incidence, 2018 - 2030
  • Fig. 145 Key country dynamics
  • Fig. 146 Saudi Arabia biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 147 Cancer incidence, 2018 - 2030
  • Fig. 148 Key country dynamics
  • Fig. 149 UAE biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 150 Cancer incidence, 2018 - 2030
  • Fig. 151 UAE import and export details
  • Fig. 152 Key country dynamics
  • Fig. 153 Kuwait biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 154 Cancer incidence, 2018 - 2030
  • Fig. 155 Kuwait imports and export details
  • Fig. 156 Rest of MEA biopharmaceutical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 157 Company/competition categorization
  • Fig. 160 Strategy mapping